ArticleEpilepsy & behavior : E&B2020
Cannabis constituents reduce seizure behavior in chemically-induced and scn1a-mutant zebrafish.
Article in Epilepsy & behavior : E&B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- A staged zebrafish-mouse screening strategy for antiseizure compound prioritization.Neuropharmacology · 2026Article
- In Vivo Characterization of Synthetic Cannabidiol Analogs for Seizure Suppression in Zebrafish.ACS chemical neuroscience · 2026Article
- Exploring Linalool-Based Phytotherapy for Excitatory/Inhibitory Imbalance in Alzheimer's Disease: A Review of Lavender and Cannabis Therapeutic Effects on Sleep, Seizures, and Cognition.Phytotherapy research : PTR · 2026Review
- Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.British journal of clinical pharmacology · 2026Review
- Drug discovery and preclinical testing of drug candidates for developmental and epileptic encephalopathies.Epilepsia · 2025Review
- Exploring Cannabinoid Effects Using Zebrafish (International journal of molecular sciences · 2025Review
- Automated detection of complex zebrafish seizure behavior at scale.Communications biology · 2025Article
- The Anticonvulsant Effects of Different Cannabis Extracts in a Zebrafish Model of Epilepsy.Biomolecules · 2025Article
- Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder.International journal of molecular sciences · 2024Review
- The Use of Compounds Derived fromInternational journal of molecular sciences · 2024Review
- Induction of seizures and initiation of epileptogenesis by pilocarpine in zebrafish larvae.Frontiers in molecular neuroscience · 2024Article
- Phytocannabinoids Reduce Seizures in Larval Zebrafish and Affect Endocannabinoid Gene Expression.Biomolecules · 2023Article
- Zebrafish as an Animal Model in Cannabinoid Research.International journal of molecular sciences · 2023Review
- Review
- Zebrafish as a robust preclinical platform for screening plant-derived drugs with anticonvulsant properties-a review.Frontiers in molecular neuroscience · 2023Review
- Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.International journal of molecular sciences · 2022Review
- A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment.Biomedicines · 2022Review
- In Vivo Evaluation ofPharmaceuticals (Basel, Switzerland) · 2021Article
- A zebrafish-centric approach to antiepileptic drug development.Disease models & mechanisms · 2021Article
- Phenotypic analysis of catastrophic childhood epilepsy genes.Communications biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Current antiepileptic drugs (AEDs) are undesirable for many reasons including the inability to reduce seizures in certain types of epilepsy, such as Dravet syndrome (DS) where in one-third of patients does not respond to current AEDs, and severe adverse effects that are frequently experienced by patients. Epidiolex, a cannabidiol (CBD)-based drug, was recently approved for treatment of DS. While Epidiolex shows great promise in reducing seizures in patients with DS, it is used in conjunction with other AEDs and can cause liver toxicity. To investigate whether other cannabis-derived compounds could also reduce seizures, the antiepileptic effects of CBD, Δ9-tetrahydrocannabinol (THC), cannabidivarin (CBDV), cannabinol (CBN), and linalool (LN) were compared in both a chemically-induced (pentylenetetrazole, PTZ) and a DS (scn1Lab
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.